Chart versions

English

Portuguese

German

Polish

General information

Substance class description

Psychedelics

• 2C-T-x is a moderate MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin).-A inhibitor, can cause SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Syndrome when combined with monoamine releasers, SSRIs or other MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). inhibitors.
  • https://www.ncbi.nlm.nih.gov/pubmed/15801832

• αMT is a reversible MAOIMonoamine oxidase inhibitor are drugs that inhibit the action of monoamine oxidase in the brain and so allow monoamines to accumulate. in higher doses (the danger rises exponentially as αMT doses approach 150 mg due to increased monoamine release and increased MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). inhibition), can cause SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Syndrome when combined with monoamine releasers, SSRIs or other MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). inhibitors.
  • https://www.ncbi.nlm.nih.gov/pubmed/13851725
  • https://www.jstage.jst.go.jp/article/jphs1951/41/2/41_2_191/_article
  • https://www.ncbi.nlm.nih.gov/pubmed/13898151

• 5-MeO substituted tryptamines are SNRIs or SNDRIs and therefore should not be combined with other reuptake inhibitors or MAOIs.
  • http://www.ncbi.nlm.nih.gov/pubmed/17382495
  • http://www.sciencedirect.com/science/article/pii/S0014299906013811
  • http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028383/
  • http://www.ncbi.nlm.nih.gov/pubmed/15214625
  • http://www.ncbi.nlm.nih.gov/pubmed/16356341

Opioids

• Tramadol acts as a μ-opioid receptor agonistA substance that initiates a physiological response when combined with a receptor., serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. releasing agent (SRA), serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. and norepinephrine reuptake inhibitor (SNRISerotonin–Norepinephrine Reuptake Inhibitor), NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor antagonistA substance that interferes with or inhibits the physiological action of another., 5-HT2C receptor antagonistA substance that interferes with or inhibits the physiological action of another., 5 nicotinic acetylcholine receptor antagonistA substance that interferes with or inhibits the physiological action of another., TRPV1 receptor agonistA substance that initiates a physiological response when combined with a receptor., and M1 and M3 muscarinic acetylcholine receptor antagonistA substance that interferes with or inhibits the physiological action of another.. It can cause seizures, serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. syndrome and even death when combined with certain stimulants and other reuptake inhibitors.
  • https://www.ncbi.nlm.nih.gov/pubmed/2849950
  • https://www.ncbi.nlm.nih.gov/pubmed/8955860
  • https://www.ncbi.nlm.nih.gov/pubmed/9671098
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1908625/
  • https://www.ncbi.nlm.nih.gov/pubmed/9389855
  • https://www.ncbi.nlm.nih.gov/pubmed/8955860
  • https://www.ncbi.nlm.nih.gov/pubmed/15845694
  • https://www.ncbi.nlm.nih.gov/pubmed/15105221
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573343/
  • http://jpet.aspetjournals.org/content/299/1/255.long
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572317/

Specific combinations with references (work in progress)

LSD & DMT

"Low doses antagonized the effects of both hallucinogens, whereas larger doses enhanced their effects."

http://www.ncbi.nlm.nih.gov/pubmed/3006089

http://deepblue.lib.umich.edu/bitstream/handle/2027.42/26285/0000370.pdf

LSD & GHB/GBL

http://www.ncbi.nlm.nih.gov/pubmed/16483730

LSD & Opioids

http://www.ncbi.nlm.nih.gov/pubmed/547279

http://www.ncbi.nlm.nih.gov/pubmed/3006089

"Low doses antagonized the effects of both hallucinogens, whereas larger doses enhanced their effects."

http://www.ncbi.nlm.nih.gov/pubmed/3006089

http://deepblue.lib.umich.edu/bitstream/handle/2027.42/26285/0000370.pdf

LSD & Tramadol

http://www.ncbi.nlm.nih.gov/pubmed/3006089

LSD & MAOIs

http://www.ncbi.nlm.nih.gov/pubmed/8788508

http://www.ncbi.nlm.nih.gov/pubmed/108709

https://www.erowid.org/references/refs_view.php?A=ShowDocPartFrame&ID=2439&DocPartID=2199

LSD & SSRIs

http://www.nature.com/npp/journal/v14/n6/full/1380431a.html

http://www.ncbi.nlm.nih.gov/pubmed/8726753

DMT & Opioids

http://www.ncbi.nlm.nih.gov/pubmed/3006089

DMT & Tramadol

http://www.ncbi.nlm.nih.gov/pubmed/3006089

DOx & Amphetamines

http://www.ncbi.nlm.nih.gov/pubmed/1208759

Ketamine & Caffeine

http://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2009.00382.x/full

Ketamine & Alcohol

http://onlinelibrary.wiley.com/doi/10.1002/jemt.22045/abstract

Ketamine & GHB/GBL

http://www.ncbi.nlm.nih.gov/pubmed/16483730

Ketamine & Opioids

http://www.ncbi.nlm.nih.gov/pubmed/21224020

MXEMethoxetamine & DXM

http://i.imgur.com/zmqaw.jpg

http://www.sciencedirect.com/science/article/pii/S0014488607002543

MXEMethoxetamine & Amphetamines

http://www.ncbi.nlm.nih.gov/pubmed/25060403

DXM & PCP

http://i.imgur.com/zmqaw.jpg

http://www.sciencedirect.com/science/article/pii/S0014488607002543

PCP & SSRIs

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1224745/

Amphetamines & Benzodiazepines

http://www.ncbi.nlm.nih.gov/pubmed/17320309

MDMA & Caffeine

http://www.ncbi.nlm.nih.gov/pubmed/22671762

http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02065.x/full

http://link.springer.com/article/10.1007/s00213-010-1864-1

http://www.sciencedirect.com/science/article/pii/S0028390805003114

MDMA & Alcohol

http://www.ncbi.nlm.nih.gov/pubmed/21040238

http://www.ncbi.nlm.nih.gov/pubmed/21756931

MDMA & GHB/GBL

http://www.ncbi.nlm.nih.gov/pubmed/16234132

http://www.ncbi.nlm.nih.gov/pubmed/22554869

http://www.ncbi.nlm.nih.gov/pubmed/20730418

http://www.ncbi.nlm.nih.gov/pubmed/16483730

Cocaine & SSRIs

http://www.ncbi.nlm.nih.gov/pubmed/23761390

http://www.ncbi.nlm.nih.gov/pubmed/20195220

Caffeine & Alcohol

http://www.ncbi.nlm.nih.gov/pubmed/20001110

Caffeine & Tramadol

http://www.ncbi.nlm.nih.gov/pubmed/20837047

Caffeine & SSRIs

http://journals.lww.com/jpharmacogenetics/abstract/1996/06000/a_fluvoxamine_caffeine_interaction_study.3.aspx

Alcohol & GHB/GBL

http://www.ncbi.nlm.nih.gov/pubmed/15274975

Alcohol & SSRIs

http://www.ncbi.nlm.nih.gov/pubmed/15739105

GHB/GBL & Opioids

http://www.ncbi.nlm.nih.gov/pubmed/7782758

GHB/GBL & Tramadol

http://www.ncbi.nlm.nih.gov/pubmed/7782758

GHB/GBL & Benzodiazepines

http://www.ncbi.nlm.nih.gov/pubmed/16483730

GHB/GBL & MAOIs

No study, but MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). B inhibitors should enhance the effects, no interaction with MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). A.

Opioids & Benzodiazepines

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454351/

Opioids & MAOIs

http://www.ncbi.nlm.nih.gov/pubmed/17157368 (?)

http://www.ncbi.nlm.nih.gov/pubmed/2891392

http://www.if-pan.krakow.pl/pjp/pdf/2013/3_593.pdf

Opioids & SSRIs

http://www.ncbi.nlm.nih.gov/pubmed/23391344

http://www.ncbi.nlm.nih.gov/pubmed/20513454

http://www.ncbi.nlm.nih.gov/pubmed/16005413

http://www.ncbi.nlm.nih.gov/pubmed/18676387

http://www.ncbi.nlm.nih.gov/pubmed/17381671

Tramadol & Benzodiazepines

http://www.ncbi.nlm.nih.gov/pubmed/12842359

Tramadol & MAOIs

http://www.ncbi.nlm.nih.gov/pubmed/16051647

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750095/

Tramadol & SSRIs

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714818/

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750095/

Benzodiazepines & SSRIs

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446479/

http://www.ncbi.nlm.nih.gov/pubmed/9435993

MAOIs & SSRIs

http://www.ncbi.nlm.nih.gov/pubmed/24577320

Top Contributors